TrialsgrambetaRCTs are beautiful

ROCKET-AF

2011

Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and embolism in AF

In 14,264 patients with non-valvular AF at moderate-high stroke risk, rivaroxaban was non-inferior to warfarin for stroke or systemic embolism, with less intracranial bleeding.

Result

Primary endpoint: Stroke or systemic embolism

1.7 %/yr vs 2.2 %/yr. ICH 0.5 % vs 0.7 %.

Original publication
Subtopic
Anticoagulation
Design
Double-blind, double-dummy RCT
Relevance
Important: one of several pillars.
Source
Patel MR, et al. N Engl J Med. 2011;365(10):883-891.doi 10.1056/NEJMoa1009638

Discussion & critique

Warfarin TTR ~ 55 %, low by modern standards; argued to inflate rivaroxaban performance. Once-daily dosing favours adherence.

Discussed in podcasts